title: Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry.
abstract: OBJECTIVE
  We sought to evaluate the impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable stents (BRS) in routine clinical practice.
  
  
  RESULTS
  All consecutive patients undergoing BRS implantation at two centres in Munich, Germany, were included prospectively. The patient population was divided according to the diameter of the implanted BRS. Angiographic surveillance was scheduled at six to eight months after stent implantation and films were analysed in a core laboratory. A BRS with 2.5 mm diameter was implanted in 101 patients and BRS >2.5 mm diameter in 318. Baseline patient characteristics were similar in both groups. Reference vessel diameter was 2.36±0.22 mm in patients with an implanted 2.5 mm BRS and 3.03±0.40 mm in the other group (p<0.001). At angiographic follow-up, in-stent late luminal loss (0.28±0.47 mm vs. 0.25±0.52 mm, p=0.74) was similar in both groups, though binary angiographic restenosis was numerically higher in patients treated with a 2.5 mm BRS (12.5% vs. 6.1%, p=0.05). After 12 months, the rate of the composite of death, myocardial infarction or target lesion revascularisation was 15.7% vs. 12.3% (p=0.49). Definite stent thrombosis was detected in 1.0% vs. 3.1% (p=0.31).
  
  
  CONCLUSIONS
  In patients treated with BRS in routine clinical practice, angiographic and clinical outcomes were comparable in patients treated with a 2.5 mm stent as compared with those treated with a larger stent size.
authors.affiliation: Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Wiebe
authors.forename: Petra
authors.initials: P
authors.lastname: Hoppmann
authors.forename: Sebastian
authors.initials: S
authors.lastname: Kufner
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Harada
authors.forename: Roisin
authors.initials: R
authors.lastname: Colleran
authors.forename: Jonathan
authors.initials: J
authors.lastname: Michel
authors.forename: Daniele
authors.initials: D
authors.lastname: Giacoppo
authors.forename: Simon
authors.initials: S
authors.lastname: Schneider
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cassese
authors.forename: Tareq
authors.initials: T
authors.lastname: Ibrahim
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
authors.forename: Karl-Ludwig
authors.initials: KL
authors.lastname: Laugwitz
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
authors.forename: Robert A
authors.initials: RA
authors.lastname: Byrne
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects*; D000368:Aged; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D011474:Prosthesis Design; D012042:Registries; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus